• Je něco špatně v tomto záznamu ?

Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis

SD. Vasikaran, M. Miura, R. Pikner, HP. Bhattoa, E. Cavalier, IOF-IFCC Joint Committee on Bone Metabolism (C-BM)

. 2023 ; 112 (2) : 148-157. [pub] 20211130

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004476
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2002-01-01 do Před 1 rokem

Odkazy

PubMed 34846540
DOI 10.1007/s00223-021-00930-4
Knihovny.cz E-zdroje

Bone turnover markers (BTMs) are released during the bone remodelling cycle and are measurable in blood or urine, reflecting bone remodelling rate. They have been useful in elucidating the pharmacodynamics and effectiveness of osteoporosis medication in clinical trials and are increasingly used in routine clinical management of osteoporosis, especially for monitoring therapy, in addition to their use in other metabolic bone disease such as Paget's disease of bone and osteomalacia. Serum β isomerised C-terminal telopeptide of type I collagen and pro-collagen I N-terminal propeptide have been designated as reference BTMs for use in osteoporosis. In addition, bone-specific isoenzyme of alkaline phosphatase (B-ALP) secreted by osteoblasts and tartrate-resistant acid phosphatase 5b (TRACP-5b) secreted by osteoclasts are also found to be specific markers of bone formation and resorption, respectively. The concentrations of the latter enzymes in blood measured by immunoassay provide reliable measures of bone turnover even in the presence of renal failure. B-ALP is recommended for use in the assessment of renal bone disease of chronic kidney disease, and TRACP-5b shows promise as a marker of bone resorption in that condition. BTMs in blood do not suffer from biological variation to the same extent as the older BTMs that were measured in urine. Appropriate patient preparation and sample handling are important in obtaining accurate measures of BTMs for clinical use. Reference change values and treatment targets have been determined for the reference BTMs for their use in monitoring osteoporosis treatment. Further ongoing studies will enhance their clinical applications.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004476
003      
CZ-PrNML
005      
20230425141429.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00223-021-00930-4 $2 doi
035    __
$a (PubMed)34846540
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vasikaran, Samuel D $u PathWest Laboratory Medicine, Fiona Stanley Hospital, Murdoch, WA, Australia. samuel.vasikaran@health.wa.gov.au $1 https://orcid.org/0000000208313031
245    10
$a Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis / $c SD. Vasikaran, M. Miura, R. Pikner, HP. Bhattoa, E. Cavalier, IOF-IFCC Joint Committee on Bone Metabolism (C-BM)
520    9_
$a Bone turnover markers (BTMs) are released during the bone remodelling cycle and are measurable in blood or urine, reflecting bone remodelling rate. They have been useful in elucidating the pharmacodynamics and effectiveness of osteoporosis medication in clinical trials and are increasingly used in routine clinical management of osteoporosis, especially for monitoring therapy, in addition to their use in other metabolic bone disease such as Paget's disease of bone and osteomalacia. Serum β isomerised C-terminal telopeptide of type I collagen and pro-collagen I N-terminal propeptide have been designated as reference BTMs for use in osteoporosis. In addition, bone-specific isoenzyme of alkaline phosphatase (B-ALP) secreted by osteoblasts and tartrate-resistant acid phosphatase 5b (TRACP-5b) secreted by osteoclasts are also found to be specific markers of bone formation and resorption, respectively. The concentrations of the latter enzymes in blood measured by immunoassay provide reliable measures of bone turnover even in the presence of renal failure. B-ALP is recommended for use in the assessment of renal bone disease of chronic kidney disease, and TRACP-5b shows promise as a marker of bone resorption in that condition. BTMs in blood do not suffer from biological variation to the same extent as the older BTMs that were measured in urine. Appropriate patient preparation and sample handling are important in obtaining accurate measures of BTMs for clinical use. Reference change values and treatment targets have been determined for the reference BTMs for their use in monitoring osteoporosis treatment. Further ongoing studies will enhance their clinical applications.
650    _2
$a lidé $7 D006801
650    _2
$a kyselá fosfatasa rezistentní k tartarátu $7 D000071681
650    12
$a osteoporóza $x farmakoterapie $7 D010024
650    12
$a metabolické nemoci kostí $7 D001851
650    _2
$a kolagen typu I $7 D024042
650    _2
$a alkalická fosfatasa $7 D000469
650    _2
$a remodelace kosti $7 D016723
650    _2
$a biologické markery $7 D015415
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Miura, Masakazu $u Faculty of Pharmaceutical Sciences, Hokuriku University/Hokuriku University Healthy Aging Research Group, 3 Ho Kanagawa-machi, Kanazawa City, Ishikawa, 9201181, Japan
700    1_
$a Pikner, Richard $u Department of Clinical Biochemistry and Bone Metabolism, Klatovska Hospital, Klatovy, Czech Republic $u Department of Clinical Biochemistry and Haematology, Faculty of Medicine Pilsen, Charles University Prague, Pilsen, Czech Republic $u Faculty of Health Care Studies, University of West Bohemia, Pilsen, Czech Republic
700    1_
$a Bhattoa, Harjit P $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
700    1_
$a Cavalier, Etienne $u Department of Clinical Chemistry, University of Liège, CHU de Liège, Domaine du Sart-Tilman, 4000, Liège, Belgium
710    2_
$a IOF-IFCC Joint Committee on Bone Metabolism (C-BM)
773    0_
$w MED00000994 $t Calcified tissue international $x 1432-0827 $g Roč. 112, č. 2 (2023), s. 148-157
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34846540 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141426 $b ABA008
999    __
$a ok $b bmc $g 1924898 $s 1190685
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 112 $c 2 $d 148-157 $e 20211130 $i 1432-0827 $m Calcified tissue international $n Calcif Tissue Int $x MED00000994
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace